Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

Trending With Impact: Unconventional Method Effectively Targets NSCLC

Oncotarget

September 30, 2021
In a trending paper published by Oncotarget, researchers developed a divergent strategy to treat non-small cell lung cancer (NSCLC). continue reading »

Table of Contents: Oncotarget’s Volume 12, Issue #20

Oncotarget

September 28, 2021
Read short summaries of the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 20. continue reading »

Behind the Study: Populations of Cells Resistant to EMT

Oncotarget

September 27, 2021
Dr. Herbert Levine and Dr. Mohit Kumar Jolly describe their research that was published by Oncotarget on July 7, 2020, entitled, “Epigenetic feedback and stochastic partitioning during cell division can drive resistance to EMT.” continue reading »

Behind the Study: Evaluations in TRAMP Prostate Cancer Model

Oncotarget

September 20, 2021
Dr. Yves Chabu from the University of Missouri describes a research paper he co-authored in 2020 that was published by Oncotarget, entitled, “Evaluations of CRC2631 toxicity, tumor colonization, and genetic stability in the TRAMP prostate cancer model.” continue reading »

New Study: Nanoparticles Target Acute Myeloid Leukemia

Oncotarget

September 15, 2021
Researchers developed a nanoparticle-based T cell engager (nanoTCE) technology believed to be capable of targeting any immune cell and cancer of interest. NanoTCE efficacy was examined in acute myeloid leukemia. continue reading »